Skip to content
CSE: XRX.CN 0.17 0.00 0.00%  
XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
    • Metabolic Syndrome / Diabetes
    • Hypertension
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

Reports and Filings

XORTX Financial Statements and MD&A

2018
Q4 Interim Financial Statement

2017

2016

2015

Press Releases

  • XORTX Receives FDA Response on Orphan Drug Designation Application November 26, 2018
  • XORTX Announces Appointment of CFO November 6, 2018
  • XORTX Announces Revision to Polycystic Kidney Disease Clinical Development Plan October 23, 2018
  • XORTX Announces New Clinical Advisory Board Members October 15, 2018
  • XORTX Announces Submission of Orphan Drug Designation Application September 10, 2018
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress